Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines

Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer

(2012) Tristan Sissung et al.   Anti-Cancer Agents in Medicinal Chemistry

Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines

(2010) Monica Civallero et al.   LEUKEMIA & LYMPHOMA

Rituximab–lenalidomide–dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma

(2010) Vadim Ivanov et al.   LEUKEMIA & LYMPHOMA

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

(2010) Taimur Sher et al.   LEUKEMIA & LYMPHOMA

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

(2009) Thomas E. Witzig et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

(2008) A. Ferrajoli et al.   BLOOD

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Enzastaurin, a Protein Kinase C  Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells

(2008) K.-W. Lee et al.   CANCER RESEARCH

Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer

(2008) Davide Mauri et al.   JNCI-Journal of the National Cancer Institute

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

(2008) Enrique M Ocio et al.   LANCET ONCOLOGY

The oral protein-kinase Cβinhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines

(2008) Antonino Neri et al.   LEUKEMIA & LYMPHOMA

Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cβ inhibitor, in non-small cell lung cancer cells

(2008) Floriana Morgillo et al.   MOLECULAR CANCER THERAPEUTICS

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

(2007) F. Morschhauser et al.   ANNALS OF ONCOLOGY